Lower Nerve Growth Factor Levels in Major Depression and Suicidal Behaviors: Effects of Adverse Childhood Experiences and Recurrence of Illness

Background: Major depressive disorder (MDD) and its severe subtype, major dysmood disorder (MDMD), are distinguished by activation of inflammatory and growth factor subnetworks, which are associated with recurrence of illness (ROI) and adverse childhood experiences (ACE). Nerve growth factor (NGF) plays a crucial role in facilitating neuro-immune communications and may regulate the inflammatory response. Methods: The present study examined the effects of ACE and ROI on culture supernatant NGF, stem cell factor (SCF), stem cell GF (SCGF), hepatocyte GF (HGF), and macrophage colony stimulating factor (M-CSF), in relation to a neurotoxicity (NT) cytokine profile. Results: NGF levels are lower in MDD (p=0.003), particularly MDMD (p<0.001), as compared with normal controls. ROI and ACE were significantly and inversely associated with NGF ([≤]0.003) and the NGF/NT ratio ([≤]0.001), whereas there are no effects of ACE and ROI on SCF, SCGF, HGF, or M-CSF. Lowered NGF (p=0.003) and the NGF/NT ratio (p<0.001) are highly significantly and inversely associated with the severity of the current depression phenome, conceptualized as a latent vector extracted from the current severity of depression, anxiety, and suicidal behaviors. We found that one validated and replicable latent vector could be extracted from NGF, ROI, and the depression phenome, which therefore constitutes a novel ROI-NGF-pathway-phenotype. ACE explained 59.5% of the variance in the latter pathway phenotype (p<0.001). Conclusions: The imbalance between decreased NGF and increased neurotoxic cytokines during the acute phase of severe depression may contribute to decreased neuroprotection, increased neuro-affective toxicity, and chronic mild inflammation.

[1]  A. Sughondhabirom,et al.  T cell activation via the CD40 ligand and transferrin receptor and deficits in T regulatory cells are associated with major depressive disorder and severity of depression , 2023, medRxiv.

[2]  W. Gan,et al.  Reduced levels of NGF shift astrocytes toward a neurotoxic phenotype , 2023, Frontiers in Cell and Developmental Biology.

[3]  S. Sirivichayakul,et al.  Methamphetamine (MA) use, MA dependence, and MA-induced psychosis are associated with increasing aberrations in the compensatory immunoregulatory system and interleukin-1α and CCL5 levels , 2023, medRxiv.

[4]  K. Plaimas,et al.  Adverse childhood trauma and reoccurrence of illness impact the gut microbiome, which affects suicidal behaviors and the phenome of major depression: towards enterotypic-phenotypes , 2023, medRxiv.

[5]  Michael Maes,et al.  Research and Diagnostic Algorithmic Rules (RADAR) and RADAR Plots for the First Episode of Major Depressive Disorder: Effects of Childhood and Recent Adverse Experiences on Suicidal Behaviors, Neurocognition and Phenome Features , 2022, medRxiv.

[6]  S. Nunes,et al.  Research and Diagnostic Algorithmic Rules (RADAR) for mood disorders, recurrence of illness, suicidal behaviors, and the patients lifetime trajectory , 2022, medRxiv.

[7]  H. Al-Hakeim,et al.  The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium , 2022, medRxiv.

[8]  M. Maes,et al.  False dogmas in mood disorders research: Towards a nomothetic network approach , 2022, World journal of psychiatry.

[9]  M. Kubera,et al.  Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles , 2022, Cells.

[10]  Michael Maes Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self , 2022, Journal of personalized medicine.

[11]  P. Gałecki,et al.  The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach , 2022, medRxiv.

[12]  M. Tang,et al.  The role of pro- and mature neurotrophins in the depression , 2021, Behavioural Brain Research.

[13]  M. Fiore,et al.  Nerve Growth Factor, Stress and Diseases. , 2020, Current medicinal chemistry.

[14]  K. Jansen,et al.  Serum level of nerve growth factor is a potential biomarker of conversion to bipolar disorder in women with major depressive disorder , 2019, Psychiatry and clinical neurosciences.

[15]  A. Mondal,et al.  Direct and indirect evidences of BDNF and NGF as key modulators in depression: role of antidepressants treatment , 2018, The International journal of neuroscience.

[16]  M. Maes,et al.  The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder , 2018, Molecular Neurobiology.

[17]  L. Bracci-Laudiero,et al.  NGF and Its Receptors in the Regulation of Inflammatory Response , 2017, International journal of molecular sciences.

[18]  S. Skaper Mast Cell - Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications. , 2016, CNS & neurological disorders drug targets.

[19]  M. Papp,et al.  Chronic mild stress influences nerve growth factor through a matrix metalloproteinase-dependent mechanism , 2015, Psychoneuroendocrinology.

[20]  A. Micera,et al.  Nerve Growth Factor: A Focus on Neuroscience and Therapy , 2015, Current neuropharmacology.

[21]  Pao-Yen Lin,et al.  Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-analysis and systematic review , 2015, Neuropsychiatric disease and treatment.

[22]  Dirceu da Silva,et al.  Structural Equation Modeling with the SmartPLS , 2014 .

[23]  R. Hellweg,et al.  Reduced nerve growth factor levels in stress-related brain regions of folate-deficient mice , 2013, Neuroscience.

[24]  H. Abelaira,et al.  Treatment with tianeptine induces antidepressive-like effects and alters the neurotrophin levels, mitochondrial respiratory chain and cycle Krebs enzymes in the brain of maternally deprived adult rats , 2013, Metabolic Brain Disease.

[25]  Barbara Stanley,et al.  The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. , 2011, The American journal of psychiatry.

[26]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[27]  Jee-Yin Ahn,et al.  Neuroprotection signaling pathway of nerve growth factor and brain-derived neurotrophic factor against staurosporine induced apoptosis in hippocampal H19-7 cells , 2010, Experimental & Molecular Medicine.

[28]  E. Alleva,et al.  The NGF saga: From animal models of psychosocial stress to stress-related psychopathology , 2009, Frontiers in Neuroendocrinology.

[29]  H. Danker-Hopfe,et al.  Differential regulation of nerve growth factor and brain-derived neurotrophic factor in a mouse model of learned helplessness , 2006, Experimental Neurology.

[30]  E. Emanuele,et al.  Raised plasma nerve growth factor levels associated with early-stage romantic love , 2006, Psychoneuroendocrinology.

[31]  Yogesh K. Dwivedi,et al.  Suicide Brain Is Associated with Decreased Expression of Neurotrophins , 2005, Biological Psychiatry.

[32]  R. Hellweg,et al.  State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations , 2004, Journal of Neural Transmission.

[33]  H. Danker-Hopfe,et al.  Measurement of Nerve Growth Factor Serum Concentration in a Psychologically Stressful Situation in Men , 2004, Stress.

[34]  R. Hellweg,et al.  Effects of different kinds of acute stress on nerve growth factor content in rat brain , 2003, Brain Research.

[35]  D. Dawbarn,et al.  Neurotrophins and neurodegeneration , 2003, Neuropathology and applied neurobiology.

[36]  F. Angelucci,et al.  Electroconvulsive Stimuli Alter the Regional Concentrations of Nerve Growth Factor, Brain-Derived Neurotrophic Factor, and Glial Cell Line-Derived Neurotrophic Factor in Adult Rat Brain , 2002, The journal of ECT.

[37]  S. Scaccianoce,et al.  Nerve growth factor brain concentration and stress: changes depend on type of stressor and age , 2000, International Journal of Developmental Neuroscience.

[38]  E. Bosmans,et al.  Negative Immunoregulatory Effects of Antidepressants: Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion , 1999, Neuropsychopharmacology.

[39]  E. Senba,et al.  Immobilization stress reduced the expression of neurotrophins and their receptors in the rat brain , 1997, Neuroscience Research.

[40]  C. Pozniak,et al.  NGF and Neurotrophin-3 Both Activate TrkA on Sympathetic Neurons but Differentially Regulate Survival and Neuritogenesis , 1997, The Journal of cell biology.

[41]  G. Taglialatela,et al.  Nerve growth factor and p75NGFR factor receptor mRNA change in rodent CNS following stress activation of the hypothalamo‐pituitary‐adrenocortical axis , 1993, Journal of neuroscience research.

[42]  P. Cosyns,et al.  Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. , 1992, Journal of affective disorders.

[43]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[44]  M. Fiore,et al.  Nerve growth factor in the psychiatric brain. , 2020, Rivista di psichiatria.

[45]  N. Unsain,et al.  Neurotrophins in the regulation of cellular survival and death. , 2014, Handbook of experimental pharmacology.

[46]  Jee-Yin Ahn,et al.  Neuroprotection signaling pathway of nerve growth factor and brain-derived neurotrophic factor against staurosporine induced apoptosis in hippocampal H19-7/IGF-IR , 2010, Experimental & Molecular Medicine.

[47]  G. Taglialatela,et al.  Nerve growth factor and neuronal cell death , 2008, Molecular Neurobiology.

[48]  P. Kittirattanapaiboon,et al.  The Validity of the Mini International Neuropsychiatric Interview (M.I.N.I)-Thai version , 2005 .

[49]  M. Maes Α Review on the Acute Phase Response in Major Depression , 1993, Reviews in the neurosciences.

[50]  C. Spielberger,et al.  Manual for the State-Trait Anxiety Inventory , 1970 .